Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab biological effect and 111In-bevacizumab imaging study in resectable melanoma
NL-OMON21967Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab in melanoma, sponsored by University Medical Center Groningen. Primary endpoints: Biological effects of bevacizumab and Distribution kinetics and uptake of 111In-bevacizumab. Started Jan 2007; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON21967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21967.